BCM
VRTX icon

Bluefin Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bluefin Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,168
Closed -$356K – 930
2014
Q3 		$356K Buy
+3,168
New +$302K 0.02% 464

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bluefin Capital Management's VRTX Position: Q4 2014 in Review

Bluefin Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2014, closing a stake of 3,168 shares — an estimated $356K sold.

Bluefin Capital Management first reported a position in VRTX in Q3 2014 and held it in 1 quarter. The position peaked at $356K in Q3 2014. 475 funds tracked by Wall St. Rank hold VRTX as of Q4 2014.

  • Bluefin Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Bluefin Capital Management sold 3,168 Vertex Pharmaceuticals shares in Q4 2014, an estimated $356K.
  • Bluefin Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Bluefin Capital Management's Vertex Pharmaceuticals position peaked at $356K in Q3 2014.
  • 475 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2014.

Based on Bluefin Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.